Provided by Tiger Fintech (Singapore) Pte. Ltd.

Akari Therapeutics PLC

1.38
-0.0200-1.43%
Post-market: 1.35-0.0300-2.17%16:05 EDT
Volume:8.07K
Turnover:11.00K
Market Cap:39.85M
PE:-0.56
High:1.39
Open:1.28
Low:1.28
Close:1.40
Loading ...
Dec 30, 2020

Correspondence

CORRESP [Cover] - Correspondence
Nov 16, 2020

important event

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Aug 11, 2020

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Jul 24, 2020

Correspondence

CORRESP [Cover] - Correspondence
Jul 17, 2020

Public Prospectus

F-1 - Registration statement for certain foreign private issuers
Jul 02, 2020

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Apr 15, 2020

Correspondence

CORRESP [Cover] - Correspondence
Mar 31, 2020

Annual Report

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
Mar 31, 2020

Report of foreign issuer

Report of foreign issuer [Rules 13a-16 and 15d-16]
Mar 30, 2020

Beneficial Ownership Change

[Amend] General statement of acquisition of beneficial ownership
Mar 04, 2020

Report of foreign issuer

Report of foreign issuer [Rules 13a-16 and 15d-16]
Feb 20, 2020

Report of foreign issuer

Report of foreign issuer [Rules 13a-16 and 15d-16]
Feb 14, 2020

Beneficial Ownership Change

[Amend] Statement of acquisition of beneficial ownership by individuals
Jan 27, 2020

Report of foreign issuer

Report of foreign issuer [Rules 13a-16 and 15d-16]
Jan 10, 2020

Report of foreign issuer

Report of foreign issuer [Rules 13a-16 and 15d-16]
Dec 23, 2019

Report of foreign issuer

Report of foreign issuer [Rules 13a-16 and 15d-16]
Dec 02, 2019

Report of foreign issuer

Report of foreign issuer [Rules 13a-16 and 15d-16]
Nov 27, 2019

Report of foreign issuer

Report of foreign issuer [Rules 13a-16 and 15d-16]
Nov 27, 2019

Report of foreign issuer

Report of foreign issuer [Rules 13a-16 and 15d-16]
Oct 24, 2019

Correspondence

[Cover]Correspondence